Consensus Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 04/09/2026 BST			5-day change	1st Jan Change
126.75 ^USD	-0.98%		+1.91%	+28.33%

08-31	Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services	CI
08-28	US FDA approves Takeda, Protagonist's drug for rare blood cancer	RE

Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

607ecf2bd6c2aaf849a0a5be2e13222._lyoirPIVHyMwlXTsWhTIwZV1D61zvrOSl64MG09LSk.rG75zPuuGhT1q3ihhwwCSGk7t2HZ-q23KA-PRgl_HX-NNObl_oQOS9yJNg~3fd73209943f78e01a88279d6c3d2f92

Analysts' recommendations: Incyte Corporation

08-20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
08-17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
08-13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
08-03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
08-03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
07-31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
07-30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
07-29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
07-29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
07-29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
07-29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
07-29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
07-29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
07-29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
07-29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
07-29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT
07-29	RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating	MT
07-28	Oppenheimer Raises Incyte Price Target to $120 From $107	MT
07-28	Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept	MT
07-28	Wells Fargo Adjusts Price Target on Incyte to $116 From $101	MT
07-23	JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating	MT
07-22	Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating	MT
07-15	BofA Securities Raises Incyte Price Target to $136 From $124	MT
07-14	Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INCYTE CORPORATION					-0.2%
	REGENERON PHARMACEUTICALS, INC.					-0.36%
	CSL LIMITED					-4.19%
	MODERNA, INC.					-21.74%
	SAMSUNG BIOLOGICS CO.,LTD.					+33.21%
	UCB					+29.13%
	BIOGEN INC.					+5.5%
	INNOVENT BIOLOGICS, INC.					+25.25%
	SWEDISH ORPHAN BIOVITRUM AB					+8.17%
	BRIDGEBIO PHARMA, INC.					+44.67%
	Average					+11.94%
	Weighted average by Cap.					+7.36%